BridgeBio Pharma, Inc. — Director's Dealing 2021

Dec 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-28

Reporting Person: DANIELS RONALD J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-28	Common Stock	P	11745	$12.73	Acquired	11745	Direct
2021-12-28	Common Stock	S	11745	$12.80	Disposed	0	Direct
2021-12-30	Common Stock	P	10402	$14.34	Acquired	10402	Direct

Footnotes

F1: The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions.

F2: Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.

F3: Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.